Organization
Besançon
2 abstracts
Abstract
Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).Org: University Hospital Jean Minjoz, Université de Franche-Comté, Inserm RIGHT, Besançon, CHU de Bordeaux,
Abstract
Prognosis factors for long-term eribulin response in a cohort of patients with HER2-negative metastatic breast cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, CHU Besançon, Besançon, Department of medical onclogy, Peking Union Medical College Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,